• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    January 22, 2021 - Coronavirus (COVID-19) Update: January 22, 2021

    1/22/21 3:54:10 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care
    Get the next $MMM alert in real time by email
    For Immediate Release:
    January 22, 2021

    The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

    • The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found that in a variety of online postings from as early as March 2020, the defendant, Johnny T. Stine, claimed to have a COVID-19 vaccine that he offered to inject in customers for $400-$1000 each. Stine’s company, North Coast Biologics, had previously received a warning letter from the agency for promoting an unapproved COVID-19 vaccine product.

      “Unproven injectable vaccines purported to prevent or treat COVID-19, made from unknown substances under unknown conditions, present significant health risks in and of themselves. They also can lead consumers to make lifestyle choices that increase their actual risk of infection with COVID-19, or to delay or stop appropriate medical treatment,” said Special Agent in Charge Lisa L. Malinowski, FDA Office of Criminal Investigations Los Angeles Field Office. “The FDA will continue to investigate fraudulent COVID-19 treatments and bring to justice those who try to profit from the pandemic by offering unproven and illegally marketed coronavirus products.”
    • The FDA is reissuing the Emergency Use Authorizations (EUAs) for decontamination systems that are authorized to decontaminate compatible N95 respirators for use by healthcare personnel (HCP) to prevent exposure to pathogenic biological airborne particulates when there is an insufficient supply of new respirators resulting from the Coronavirus Disease 2019 (COVID-19) pandemic. Among other things, the reissued EUAs for certain decontamination systems are now only authorized to decontaminate each compatible N95 respirator a maximum of four or fewer times.

      Based on the FDA’s review of real-world use of these systems and evidence from adverse events and scientific literature, including studies regarding N95 respirator failures from simulated and real-world use, the FDA has determined that it is appropriate to protect the public health or safety to revise certain decontamination system EUAs to limit the number of decontamination cycles and respirator reuses permitted under each authorization.
    • Today, the FDA also added two new devices to the device discontinuance list on our web page that lists medical device shortages during the COVID-19 public health emergency. There are no updates to the device shortage list at this time. The FDA will continue to update the device shortage and device discontinuance lists as the COVID-19 public health emergency evolves. Specifically, the FDA added the following devices to the device discontinuance list:
      • 3M Company's 3M Triple Layer Molded Face Mask (2042F) and 3M Triple Layer Molded Face Mask, Petite (2042FP)
      • BioFire Diagnostics, LLC's FilmArray Instrument (FLM1-ASY-0001)
    • Testing updates:
      • As of today, 319 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 237 molecular tests and sample collection devices, 69 antibody tests, and 13 antigen tests. There are 33 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, one antigen prescription at-home test, and one over-the-counter (OTC) at-home antigen test.

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

    ###


    Inquiries

    Media:
    Abby Capobianco
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

    Related Information

    Related Information
    • FAQs on Testing for SARS-CoV-2
    • Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)
    • Coronavirus Disease 2019 (COVID-19)

    Get the next $MMM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MMM

    DatePrice TargetRatingAnalyst
    1/22/2025$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    11/13/2024$184.00Neutral → Buy
    UBS
    10/22/2024Hold → Buy
    Melius
    9/6/2024$125.00Underweight
    Morgan Stanley
    7/30/2024$145.00Hold → Buy
    Argus
    7/29/2024$110.00 → $150.00Hold → Buy
    Deutsche Bank
    6/13/2024$125.00Peer Perform → Outperform
    Wolfe Research
    6/7/2024$105.00 → $120.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $MMM
    SEC Filings

    See more
    • SEC Form SD filed by 3M Company

      SD - 3M CO (0000066740) (Filer)

      5/30/25 8:15:17 AM ET
      $MMM
      Medical/Dental Instruments
      Health Care
    • 3M Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - 3M CO (0000066740) (Filer)

      5/14/25 5:18:32 PM ET
      $MMM
      Medical/Dental Instruments
      Health Care
    • 3M Company filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - 3M CO (0000066740) (Filer)

      5/12/25 4:16:24 PM ET
      $MMM
      Medical/Dental Instruments
      Health Care

    $MMM
    Leadership Updates

    Live Leadership Updates

    See more
    • 3M Annual Meeting Results

      ST. PAUL, Minn., May 13, 2025 /PRNewswire/ -- At today's Annual Meeting of Shareholders, 3M (NYSE:MMM) shareholders overwhelmingly supported each of the proposals recommended for approval by the company. Preliminary Shareholder Voting Results 3M shareholders today voted on the following business items: 1) Shareholders supported 11 directors for one-year terms to expire at the company's 2026 Annual Meeting: David P. Bozeman, President, Chief Executive Officer and Director, C.H. Robinson Worldwide, Inc.Thomas "Tony" K. Brown, retired Group Vice President, Global Purchasing, Ford

      5/13/25 4:30:00 PM ET
      $MMM
      Medical/Dental Instruments
      Health Care
    • 3M Announces New Board Appointments

      William Brown to become Chairman of the Board of DirectorsMike Roman to retire as Executive Chairman and Director and become Executive Advisor to the BoardDavid Bozeman elected to the BoardAmy Hood does not intend to stand for reelectionST. PAUL, Minn., Feb. 10, 2025 /PRNewswire/ -- 3M (NYSE:MMM) announced today changes to its Board of Directors and Board leadership structure. William M. "Bill" Brown, 3M's Chief Executive Officer and Director, has been appointed by the Board to serve as its Chairman, effective March 1, 2025 in addition to his current responsibilities.  Michael F. Roman, Executive Chairman of the Board of Directors, has announced his intention to retire as Executive Chairman,

      2/10/25 6:30:00 AM ET
      $MMM
      Medical/Dental Instruments
      Health Care
    • 3M joins consortium to accelerate semiconductor technology in the US

      ST. PAUL, Minn., Feb. 3, 2025  /PRNewswire/ -- 3M is expanding its commitment to the semiconductor industry by joining the US-JOINT Consortium, a strategic partnership of 12 leading semiconductor suppliers. The consortium drives research and development in next-generation semiconductor advanced packaging and back-end processing technologies anchored by a new cutting-edge facility in Silicon Valley. "As the demands of AI and other high performance computing technologies increase, suppliers must work together to provide comprehensive solutions to tough challenges on increasingly

      2/3/25 10:55:00 AM ET
      $MMM
      Medical/Dental Instruments
      Health Care